Title | Two-Way Regulation of MmpL3 Expression Identifies and Validates Inhibitors of MmpL3 Function in Mycobacterium tuberculosis. |
Publication Type | Journal Article |
Year of Publication | 2021 |
Authors | Grover S, Engelhart CA, Pérez-Herrán E, Li W, Abrahams KA, Papavinasasundaram K, Bean JM, Sassetti CM, Mendoza-Losana A, Besra GS, Jackson M, Schnappinger D |
Journal | ACS Infect Dis |
Volume | 7 |
Issue | 1 |
Pagination | 141-152 |
Date Published | 2021 Jan 08 |
ISSN | 2373-8227 |
Keywords | Antitubercular Agents, Bacterial Proteins, Membrane Transport Proteins, Mycobacterium tuberculosis, Mycolic Acids |
Abstract | MmpL3, an essential mycolate transporter in the inner membrane of Mycobacterium tuberculosis (Mtb), has been identified as a target of multiple, chemically diverse antitubercular drugs. However, several of these molecules seem to have secondary targets and inhibit bacterial growth by more than one mechanism. Here, we describe a cell-based assay that utilizes two-way regulation of MmpL3 expression to readily identify MmpL3-specific inhibitors. We successfully used this assay to identify a novel guanidine-based MmpL3 inhibitor from a library of 220 compounds that inhibit growth of Mtb by largely unknown mechanisms. We furthermore identified inhibitors of cytochrome bc1-aa3 oxidase as one class of off-target hits in whole-cell screens for MmpL3 inhibitors and report a novel sulfanylacetamide as a potential QcrB inhibitor. |
DOI | 10.1021/acsinfecdis.0c00675 |
Alternate Journal | ACS Infect Dis |
PubMed ID | 33319550 |
PubMed Central ID | PMC7802072 |
Grant List | U19 AI111143 / AI / NIAID NIH HHS / United States MR/R001154/1 / MRC_ / Medical Research Council / United Kingdom MR/S000542/1 / MRC_ / Medical Research Council / United Kingdom R01 AI116525 / AI / NIAID NIH HHS / United States P30 CA008748 / CA / NCI NIH HHS / United States |
Submitted by ljc4002 on August 21, 2025 - 2:37pm